Assuntos
Ética Médica , Testes Genéticos , Humanos , Testes Genéticos/ética , Testes Genéticos/tendênciasRESUMO
Genomic screening at population scale generates many ethical considerations. One is the normative role that people's preferences should play in determining access to genomic information in screening contexts, particularly information that falls beyond the scope of screening. We expect both that people will express a preference to receive such results and that there will be interest from the professional community in providing them. In this paper, we consider this issue in relation to the just and equitable design of population screening programs like reproductive genetic carrier screening (RGCS). Drawing on a pluralistic public health ethics perspective, we claim that generating and reporting information about genetic variants beyond the scope of the screening program usually lacks clinical, and perhaps personal, utility. There are both pragmatic and ethical reasons to restrict information provision to that which fits the stated purpose of the program.
Assuntos
Testes Genéticos , Programas de Rastreamento , Saúde Pública , Humanos , Testes Genéticos/éticaRESUMO
Understanding moral acceptability and willingness to use is crucial for informing policy.
Assuntos
Embrião de Mamíferos , Edição de Genes , Testes Genéticos , Herança Multifatorial , Testes Genéticos/ética , Risco , Humanos , Edição de Genes/ética , Formulação de Políticas , Estados UnidosRESUMO
U.K. and New York City efforts face cost and ethical issues.
Assuntos
Doenças Genéticas Inatas , Testes Genéticos , Programas de Rastreamento , Triagem Neonatal , Doenças Raras , Sequenciamento Completo do Genoma , Humanos , Recém-Nascido , Cidade de Nova Iorque , Testes Genéticos/economia , Testes Genéticos/ética , Programas de Rastreamento/economia , Programas de Rastreamento/ética , Triagem Neonatal/economia , Triagem Neonatal/ética , Reino Unido , Doenças Raras/diagnóstico , Doenças Raras/genética , Doenças Genéticas Inatas/diagnóstico , Doenças Genéticas Inatas/genética , Genoma Humano , Sequenciamento Completo do Genoma/economia , Sequenciamento Completo do Genoma/éticaRESUMO
The success of the Saudi Human Genome Program (SHGP), one of the top ten genomic programs worldwide, is highly dependent on the Saudi population embracing the concept of participating in genetic testing. However, genetic data sharing and artificial intelligence (AI) in genomics are critical public issues in medical care and scientific research. The present study was aimed to examine the awareness, knowledge, and attitude of the Saudi society towards the SHGP, the sharing and privacy of genetic data resulting from the SHGP, and the role of AI in genetic data analysis and regulations. Results of a questionnaire survey with 804 respondents revealed moderate awareness and attitude towards the SHGP and minimal knowledge regarding its benefits and applications. Respondents demonstrated a low level of knowledge regarding the privacy of genetic data. A generally positive attitude was found towards the outcomes of the SHGP and genetic data sharing for medical and scientific research. The highest level of knowledge was detected regarding AI use in genetic data analysis and privacy regulation. We recommend that the SHGP's regulators launch awareness campaigns and educational programs to increase and improve public awareness and knowledge regarding the SHGP's benefits and applications. Furthermore, we propose a strategy for genetic data sharing which will facilitate genetic data sharing between institutions and advance Personalized Medicine in genetic diseases' diagnosis and treatment.
Assuntos
Inteligência Artificial , Testes Genéticos/ética , Conhecimentos, Atitudes e Prática em Saúde , Disseminação de Informação/ética , Medicina de Precisão/psicologia , Adolescente , Adulto , Estudos Transversais , Feminino , Genoma Humano , Humanos , Masculino , Pessoa de Meia-Idade , Arábia Saudita , Inquéritos e QuestionáriosRESUMO
Tumour genomic profiling (TGP), conducted in search of therapeutics, sometimes reveals potentially pathogenic germline variants as secondary findings (SFs). Physicians involved in TGP are often specialised in oncology and not in clinical genetics. To better utilise SFs, we explored issues physicians have during disclosure and the potential for collaborations with clinical genetics professionals. Semi-structured interviews were conducted with 14 physicians who had experience in handling outpatient TGP at designated core hospitals for cancer genomic medicine in Japan. The data were analysed thematically. The difficulties physicians experienced during informed consent (IC) included educating patients about SFs, providing detailed information on SFs, and explaining the impact of SFs on patients' family members. When SFs were detected, physicians had reservations regarding the relevance of the disclosure criteria. Confirmatory germline tests were performed using peripheral blood when tumour-only tests detected suspected SFs. Some physicians had reservations about the necessity of confirmatory tests when they did not affect the patients' treatment options. To encourage patients to receive confirmatory tests, improvements are necessary in the healthcare system, such as insurance reimbursements, education for physicians so that they can provide a better explanation to their patients, and genetic literacy of physicians and patients. The physicians offered insights into the challenges they experienced related to IC, disclosure of SFs, and expectations for active collaborations with clinical genetics professionals. Wider healthcare insurance coverage and better genetic literacy of the population may lead to more patients taking confirmatory tests when SFs are suspected.
Assuntos
Revelação/ética , Testes Genéticos/ética , Achados Incidentais , Neoplasias/genética , Médicos/psicologia , Adulto , Idoso , Atitude , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Neoplasias/diagnóstico , Neoplasias/psicologiaAssuntos
Genes BRCA1/fisiologia , Genes BRCA2/fisiologia , Testes Genéticos/ética , Neoplasias , Administração dos Cuidados ao Paciente , Aconselhamento Genético/ética , Aconselhamento Genético/métodos , Aconselhamento Genético/psicologia , Predisposição Genética para Doença/psicologia , Humanos , Masculino , Anamnese/métodos , Saúde do Homem , Mutação , Neoplasias/genética , Neoplasias/patologia , Neoplasias/psicologia , Neoplasias/terapia , Administração dos Cuidados ao Paciente/métodos , Medição de Risco/métodosRESUMO
BACKGROUND: Pulmonary arterial hypertension (PAH) has an identifiable genetic cause in 5% of all PAH cases. Due to health benefits conferred by the early detection of PAH and the recent identification of additional PAH-associated genes, we decided to offer (extended) genetic testing to all incident and prevalent idiopathic PAH (iPAH) and pulmonary veno-occlusive disease (PVOD) patients in our clinic. Here, we report the lessons learned from (re-)contacting iPAH/PVOD patients concerning the uptake and analysis of identified PAH-associated genes and patient perspectives of the approach. METHODS: Between January 2018 and April 2020, all iPAH/PVOD patients who were not previously genetically tested (contact group) and those who tested negative on prior analysis of BMPR2 and SMAD9 variants (re-contact group) were (re-)contacted for (additional) genetic testing. RESULTS: With our approach, 58% of patients (84 out of 165) opted for genetic counselling, and a pathogenic variant was found in 12% of cases (n = 10) (re-contact group, 11%, and contact group, 13%). Eighty-six percent of participants of the survey study appreciated being (re-)contacted for genetic testing. Mild psychosocial impacts were observed. CONCLUSIONS: Our report shows the importance of (re-)contact and interest of patients (as indicated by the uptake, mild psychosocial impact and appreciation) in PAH.
Assuntos
Atitude , Testes Genéticos/métodos , Hipertensão Pulmonar/genética , Pacientes/psicologia , Adulto , Idoso , Receptores de Proteínas Morfogenéticas Ósseas Tipo II/genética , Feminino , Testes Genéticos/ética , Humanos , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/psicologia , Masculino , Pessoa de Meia-Idade , Proteína Smad8/genéticaRESUMO
Machine learning methods applied to large genomic datasets (such as those used in GWAS) have led to the creation of polygenic risk scores (PRSs) that can be used identify individuals who are at highly elevated risk for important disease conditions, such as coronary artery disease (CAD), diabetes, hypertension, breast cancer, and many more. PRSs have been validated in large population groups across multiple continents and are under evaluation for widespread clinical use in adult health. It has been shown that PRSs can be used to identify which of two individuals is at a lower disease risk, even when these two individuals are siblings from a shared family environment. The relative risk reduction (RRR) from choosing an embryo with a lower PRS (with respect to one chosen at random) can be quantified by using these sibling results. New technology for precise embryo genotyping allows more sophisticated preimplantation ranking with better results than the current method of selection that is based on morphology. We review the advances described above and discuss related ethical considerations.
Assuntos
Embrião de Mamíferos , Predisposição Genética para Doença , Testes Genéticos/ética , Testes Genéticos/métodos , Herança Multifatorial , HumanosRESUMO
Molecular genetic pathology (MGP) is a subspecialty of pathology and medical genetics and genomics. Genomic testing, which is defined as that which generates large data sets and interrogates large segments of the genome in a single assay, is increasingly recognized as essential for optimal patient care through precision medicine. The most common genomic testing technologies in clinical laboratories are next-generation sequencing and microarray. It is essential to train in these methods and to consider the data generated in the context of the diagnosis, medical history, and other clinical findings of individual patients. Accordingly, updating the MGP fellowship curriculum to include genomics is timely, important, and challenging. At the completion of training, an MGP fellow should be capable of independently interpreting and signing out results of a wide range of genomic assays and, given the appropriate context and institutional support, of developing and validating new assays in compliance with applicable regulations. The Genomics Task Force of the MGP Program Directors, a working group of the Association for Molecular Pathology Training and Education Committee, has developed a genomics curriculum framework and recommendations specific to the MGP fellowship. These recommendations are presented for consideration and implementation by MGP fellowship programs with the understanding that MGP programs exist in a diversity of clinical practice environments with a spectrum of available resources.
Assuntos
Currículo , Educação de Pós-Graduação em Medicina/métodos , Bolsas de Estudo , Genômica/educação , Genômica/métodos , Patologistas/educação , Patologia Molecular/educação , Testes Genéticos/ética , Testes Genéticos/legislação & jurisprudência , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Laboratórios Clínicos , Medicina de Precisão/métodos , Manejo de EspécimesRESUMO
What are the ethical perspectives of preimplantation genetic testing in patients using/considering PGT-A compared to those using/considering PGT-M? A 17-item questionnaire administered online was used to assess ethical perspectives in US patients who recently used/considered PGT-A (n=80) vs. those who used/considered PGT-M (n=72). Kruskal-Wallis, Chi-square, and Fisher exact tests were conducted with STATA. Most PGT-A and PGT-M users/considerers supported using PGT to screen for diseases fatal in childhood (86-89%) and those causing lifelong disabilities (76-79%) and opposed using PGT to screen for non-medical physical (80-87%) or intellectual traits (74-86%). Both groups agreed that PGT aids in parental decision-making, although some expressed concern over its potential to lead to unforeseen consequences for society and the PGT offspring. More PGT-M than PGT-A users/considerers opposed implanting genetically abnormal embryos when requested by parents (29% PGT-A vs. 56% PGT-M, p = 0.007). For embryo disposition, more PGT-A users/considerers favored freezing (95% PGTA vs. 82% PGT-M, p = 0.018) or donating genetically normal embryos to research (73% PGT-A vs. 57% PGT-M, p = 0.044), while more PGT-M users/considerers supported donating embryos with known genetic abnormalities to research (56% PGT-A vs. 81% PGT-M, p = 0.001). Regardless of the reason for using PGT, users generally agreed on the acceptable and unacceptable uses for it, as well as the potential societal impact. PGT-M users/considerers expressed more opposition than PGT-A users/considerers to implanting embryos with a genetic alteration when requested by the parents.
Assuntos
Aneuploidia , Blastocisto/fisiologia , Tomada de Decisões/ética , Testes Genéticos/ética , Diagnóstico Pré-Implantação/ética , Adulto , Feminino , Testes Genéticos/métodos , Humanos , Pessoa de Meia-Idade , Gravidez , Diagnóstico Pré-Implantação/métodos , Adulto JovemRESUMO
Healthcare systems are increasingly considering widespread implementation of rapid genomic testing of critically ill children, but evidence on the value of the benefits generated is lacking. This information is key for an optimal implementation into healthcare systems. A discrete choice experiment survey was designed to elicit preferences and values for rapid genomic testing in critically ill children. The survey was administered to members of the Australian public and families with lived experience of rapid genomic testing. A Bayesian D-efficient explicit partial profiles design was used, and data were analysed using a panel error component mixed logit model. Preference heterogeneity was explored using a latent class model and fractional logistic regressions. The public (n = 522) and families with lived experiences (n = 25) demonstrated strong preferences for higher diagnostic yield and clinical utility, faster result turnaround times, and lower cost. Society on average would be willing to pay an additional AU$9510 (US$6657) for rapid (2 weeks results turnaround time) and AU$11,000 (US$7700) for ultra-rapid genomic testing (2 days turnaround time) relative to standard diagnostic care. Corresponding estimates among those with lived experiences were AU$10,225 (US$7158) and AU$11,500 (US$8050), respectively. Our work provides further evidence that rapid genomic testing for critically ill children with rare conditions generates substantial utility. The findings can be used to inform cost-benefit analyses as part of broader healthcare system implementation.